These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 16110137

  • 1. Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma.
    Sparano JA, Negassa A, Lansigan E, Locke R, De Silva CR, Wiernik PH.
    Med Oncol; 2005; 22(3):257-67. PubMed ID: 16110137
    [Abstract] [Full Text] [Related]

  • 2. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
    Gómez H, Mas L, Casanova L, Pen DL, Santillana S, Valdivia S, Otero J, Rodriguez W, Carracedo C, Vallejos C.
    J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
    [Abstract] [Full Text] [Related]

  • 3. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL, Palackdharry CS, Padavic K, Haas N, Kilpatrick D, Langer C, Comis R.
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphoma.
    Salman H, Perez A, Sparano JA, Ratech H, Negassa A, Hopkins U, Villani G, Fuks J, Wiernik PH.
    Am J Clin Oncol; 2003 Aug; 26(4):338-43. PubMed ID: 12902881
    [Abstract] [Full Text] [Related]

  • 5. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy.
    Sparano JA, Wiernik PH, Leaf A, Dutcher JP.
    J Clin Oncol; 1993 Jun; 11(6):1071-9. PubMed ID: 8501493
    [Abstract] [Full Text] [Related]

  • 6. Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.
    Gordon LI, Anderson J, Habermann TM, Winter JN, Glick J, Schilder RJ, Cassileth P.
    J Clin Oncol; 1996 Apr; 14(4):1275-81. PubMed ID: 8648384
    [Abstract] [Full Text] [Related]

  • 7. Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF.
    Ford PA, Arbuck SG, Minniti C, Miller LL, DeMaria D, O'Dwyer PJ.
    Eur J Cancer; 1996 Apr; 32A(4):631-5. PubMed ID: 8695266
    [Abstract] [Full Text] [Related]

  • 8. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
    Stoppa AM, Bouabdallah R, Chabannon C, Novakovitch G, Vey N, Camerlo J, Blaise D, Xerri L, Resbeut M, Di Stefano D, Bardou VJ, Gastaut JA, Maraninchi D.
    J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
    [Abstract] [Full Text] [Related]

  • 9. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
    Bartlett NL, Petroni GR, Parker BA, Wagner ND, Gockerman JP, Omura GA, Canellos GP, Robert M, Johnson JL, Peterson BA.
    Cancer; 2001 Jul 15; 92(2):207-17. PubMed ID: 11466671
    [Abstract] [Full Text] [Related]

  • 10. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
    Bregni M, Siena S, Di Nicola M, Dodero A, Peccatori F, Ravagnani F, Danesini G, Laffranchi A, Bonadonna G, Gianni AM.
    J Clin Oncol; 1996 Feb 15; 14(2):628-35. PubMed ID: 8636780
    [Abstract] [Full Text] [Related]

  • 11. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH, Fay JP, Christiansen NP, Pinero L, Shah D, Stephan M, Herzig GP.
    Clin Cancer Res; 1997 Sep 15; 3(9):1519-26. PubMed ID: 9815838
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B.
    Lichtman SM, Niedzwiecki D, Barcos M, Carlisle TL, Cooper MR, Johnson JL, Peterson BA.
    Ann Oncol; 2000 Sep 15; 11(9):1141-6. PubMed ID: 11061609
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma.
    Tanosaki R, Okamoto S, Akatsuka N, Ishida A, Michikawa N, Masuda Y, Uchida H, Murata M, Kizaki M, Ikeda Y.
    Cancer; 1994 Oct 01; 74(7):1939-44. PubMed ID: 7521788
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).
    Luikart SD, Herndon JE, Hollis DR, MacDonald M, Maurer LH, Crawford J, Clamon GH, Wright J, Perry MC, Ozer H, Green MR.
    Am J Clin Oncol; 1997 Feb 01; 20(1):24-30. PubMed ID: 9020283
    [Abstract] [Full Text] [Related]

  • 18. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
    Lichtman SM, Ratain MJ, Van Echo DA, Rosner G, Egorin MJ, Budman DR, Vogelzang NJ, Norton L, Schilsky RL.
    J Natl Cancer Inst; 1993 Aug 18; 85(16):1319-26. PubMed ID: 8340944
    [Abstract] [Full Text] [Related]

  • 19. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin.
    Yau JC, Neidhart JA, Triozzi P, Verma S, Nemunaitis J, Quick DP, Mayernik DG, Oette DH, Haynes FA, Holcenberg J.
    Am J Hematol; 1996 Apr 18; 51(4):289-95. PubMed ID: 8602629
    [Abstract] [Full Text] [Related]

  • 20. A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin's lymphoma.
    Meyer RM, Gyger M, Langley R, Lespérance B, Caplan SN.
    Leuk Lymphoma; 1998 Aug 18; 30(5-6):591-600. PubMed ID: 9711921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.